- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT03794934
Structured Education Based on New Glucose Management Devices in Patients With Type 1 Diabetes Mellitus (Education)
Development and Efficacy of Individualized Professional Education Based on New Glucose Management Devices in Patients With Type 1 Diabetes Mellitus
Continuous glucose monitoring (CGM) and insulin pump, a new medical device, have been proved and highly recommended in the treatment of type 1 diabetes patients worldwide, and related technology development and market are growing rapidly.
In order to maximize the medical and socioeconomic effects of the latest blood glucose devices including CGM and insulin pump, structured education is necessary. In this study, we will develop patient-oriented structured education for patients with type 1 diabetes mellitus when applying CGM, and we will assess the efficacy of this education protocol for patients with type 1 diabetes using CGM.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
In 50 patients with type 1 diabetes with over 7% of glycated hemoglobin, whose blood glucose level is not well controlled, and who are undergoing multiple daily insulin injection therapy or insulin pump therapy, continuous glucose monitoring (CGM) is applied to obtain basal continuous glucose levels for 1 week (window period of 2 week).
These 50 patients are 1:1 randomly assigned to 2 groups including control group and intervention group. Control group (n=25) applied CGM without structured education and after 3 months of applying CGM, continuous glucose data for 2 consecutive weeks and HbA1c level, and other glycometabolic parameters are collected. As a sequential extension clinical trial, those 25 patients in control group are provided structured education, followed by applying CGM for 3 months. Continuous glucose levels for 2 consecutive weeks and HbA1c level, and other glycometabolic parameters are collected.
In Intervention group (n=25), structured education program is provided for each patient from the time of enrollment, followed by applying CGM for 3 months. Continuous glucose levels for 2 consecutive weeks and HbA1c level and other blood tests are performed after the 3 months.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Seoul, Republika Korei, 135-710
- Rekrutacyjny
- Samsung Medical Center
-
Kontakt:
- Jae Hyeon Kim, M.D.,Ph. D
- Numer telefonu: 82-2-3410-1580
- E-mail: jaehyeonmd.kim@samsung.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Over 18 years old - under 70 years old patients with Type 1 diabetes
- Those who plan to use CGM G5
- Patients who consented to use CGM G5 in conjunction with Clarity
- Those who are using multiple insulin injections or insulin pumps for at least 3 months
- Those whose fasting c-peptide <0.6 ng / dL, or stimulated c-peptide <1.8 ng / dL
- Those with a glycated hemoglobin of 7.0% or more within the last 3 months
- Those who have never used a CGM for more than a month
- For women of childbearing age, those who agree to use appropriate contraception during the trial
- Those who voluntarily signed the agreement after the explanation of the clinical trial
Exclusion Criteria:
- Those with a history of severe hypoglycemia and acute ketoacidosis within the last 3 months
- Patients with chronic renal function greater than or equal to stage 4 (estimated glomerular filtration rate [assessed by MDRD (modification of diet in renal disease] <30 )
- Patients with acute myocardial infarction, unstable angina, coronary artery disease or stroke within the last 3 months
- Patients with adrenal insufficiency, pituitary dysfunction, medically uncontrolled hyperthyroidism or hypothyroidism
- Those taking medications that can affect the glucose metabolism (eg, corticosteroids, immunostimulants, etc.)
- Pregnant and lactating women
- A person who is deemed unsuitable for participation in clinical trials by examiners
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Komparator placebo: Control
Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply
|
Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
|
Aktywny komparator: Intervention
provide structured education when applying CGM for 3 months
|
Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of time in target range 70-180 mg/dL
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in target range 70-180 mg/dL by continuous glucose monitoring system
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of time in level 2 hypoglycemia (<54mg/dL)
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in level 2 hypoglycemia (<54mg/dL) by continuous glucose monitoring system
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in level 1 hypoglycemia (<70-54mg/dL)
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in level 1 hypoglycemia (<70-54mg/dL) by continuous glucose monitoring system
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in level 1 hyperglycemia (>180mg/dL)
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in level 1 hyperglycemia (>180mg/dL) by continuous glucose monitoring system
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in level 2 hyperglycemia (>250mg/dL)
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in level 2 hyperglycemia (>250mg/dL) by continuous glucose monitoring system
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Glycemic variability, reported as coefficient of variance (CV)
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Glycemic variability, reported as coefficient of variance (CV) by continuous glucose monitoring system
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Glycemic variability, reported as standard deviation (SD)
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Glycemic variability, reported as standard deviation (SD) by continuous glucose monitoring system
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Mean glucose by continuous glucose monitoring system
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Mean glucose by continuous glucose monitoring system
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
HbA1C
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
HbA1C
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
glycated albumin
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
glycated albumin
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Personalized education time for each patient
Ramy czasowe: baseline (intervention group) and 3months (for extension study in control group)
|
Personalized education time for each patient
|
baseline (intervention group) and 3months (for extension study in control group)
|
Frequency of hypoglycemia
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Frequency of hypoglycemia
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Adverse event
Ramy czasowe: 3months (control and intervention groups) and 6months (for extension study in control group)
|
Adverse event occurred
|
3months (control and intervention groups) and 6months (for extension study in control group)
|
Percentage of time in target range 70-180 mg/dL
Ramy czasowe: 6months (for extension study in control group)
|
Percentage of time in target range 70-180 mg/dL by continuous glucose monitoring system
|
6months (for extension study in control group)
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 2018-12-108
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Cukrzyca typu 1
-
Bruce A. BuckinghamZakończonyCukrzyca typu 1 | Cukrzyca autoimmunologiczna | Cukrzyca młodzieńcza | Cukrzyca, Mellitus, Typ 1Stany Zjednoczone
-
Leiden University Medical CenterZakończonyGruczolak przysadki | Guz przysadki | Diabetes Insipidus Cranial Type | Dokrewny; NiedobórHolandia
-
Centre Hospitalier Universitaire de LiegeSanofi; Takeda; University of Liege; Orchard Therapeutics; Centre Hospitalier Régional... i inni współpracownicyRekrutacyjnyWrodzony przerost nadnerczy | Hemofilia A | Hemofilia B | Mukopolisacharydoza I | Mukopolisacharydoza II | Mukowiscydoza | Niedobór alfa 1-antytrypsyny | Anemia sierpowata | Anemia Fanconiego | Przewlekła choroba ziarniniakowa | Choroba Wilsona | Ciężka wrodzona neutropenia | Niedobór transkarbamylazy ornityny | Mukopolisacharydoza... i inne warunkiBelgia
-
UK Kidney AssociationRekrutacyjnyZapalenie naczyń | AL Amyloidoza | Stwardnienie guzowate | Choroba Fabry'ego | Cystynuria | Ogniskowe segmentowe stwardnienie kłębuszków nerkowych | Nefropatia IgA | Syndrom Barttera | Czysta aplazja czerwonokrwinkowa | Nefropatia błoniasta | Atypowy zespół hemolityczno-mocznicowy | Autosomalna dominująca policystyczna... i inne warunkiZjednoczone Królestwo